Researchers at the University of Sydney have used human stem cells to make pain-killing neurons that provide lasting relief in mice, without side effects, in a single treatment. The next step is to perform extensive safety tests in rodents and pigs, and then move to human patients suffering chronic pain within the next five years.
If the tests are successful in humans, it could be a major breakthrough in the development of new non-opioid, non-addictive pain management strategies for patients, the researchers said.
“Thanks to funding from the NSW Ministry of Health, we are already moving towards testing in humans,” said Professor Greg Neely, a leader in pain research at the Charles Perkins Centre and the School of Life and Environmental Sciences.
“Nerve injury can lead to devastating neuropathic pain and for the majority of patients there are no effective therapies. This breakthrough means for some of these patients, we could make pain-killing transplants from their own cells, and the cells can then reverse the underlying cause of pain.”
Published today in the peer-reviewed journal Pain, the team used human induced pluripotent stem cells (iPSC) derived from bone marrow to make pain-killing cells in the lab, then put them into the spinal cord of mice with serious neuropathic pain. The development of iPSC won a Nobel Prize in 2012.
“Remarkably, the stem-cell neurons promoted lasting pain relief without side effects,” co-senior author Dr Leslie Caron said. “It means transplant therapy could be an effective and long-lasting treatment for neuropathic pain. It is very exciting.”
John Manion, a PhD student and lead author of the paper said: “Because we can pick where we put our pain-killing neurons, we can target only the parts of the body that are in pain. This means our approach can have fewer side effects.”
The stem cells used were derived from adult blood samples.
Chronic pain is defined as persistent pain that continues after the original injury has healed. It comes in two forms: inflammatory pain and neuropathic pain.
This study in mice looked at neuropathic ‘pain’, which occurs after damage to the nervous system and, in humans, is usually described as an electrical or shooting pain.
Neuropathic pain can occur in human conditions such as:
Lack of effective treatments for chronic pain has led to an opioid epidemic in the US, where since 2000, around 200,000 Americans have died from prescription opioid overdoses. It is estimated by the Centres for Disease Control and Prevention that more than two million Americans are currently abusing or dependent on opioids.
“Most astonishingly, opioids are not even an effective treatment for chronic pain, but clinicians have few other options,” Professor Neely said.
“Existing treatments for neuropathic pain necessitate long term treatment with repurposed anti-convulsants and anti-depressants. These treatments are not specific for pain and have extensive side effects and importantly, these drugs together seem to really help only around 25 percent of patients.
"Virtually everyone will experience some form of chronic (untreatable) pain at some stage in their lives,” Professor Neely said. “In view of this immense and unmet problem, developing new non-opioid, non-addictive, pain management strategies are critical for our ageing society.”
The total financial cost of chronic pain in Australia in 2018 was estimated to be $139.3 billion
Professor Neely’s team work in functional genomics and study chronic pain at the Charles Perkins Centre and he heads the Sydney Genome Editing Initiative at the University of Sydney.
The team has completed a whole genome dissection of acute pain, published in Cell, and developed a chronic pain assay in the fruit fly.
The same team found an antidote to the box jellyfish sting, published in the prestigious journal Nature Communications, while studying deadly Australian creatures in order to understand what causes pain and what might block pain.
“Most of our work is directed at developing non-addictive pain killers for humans,” said Professor Neely. “We are throwing everything we know at this problem.”